KaloBios, circling the drain after a slew of clinical failures, said last week it was finally packing it in, recruiting a liquidation consultant to help it gradually wind down operations. But the company saw its share price rocket up more than 700% on Wednesday evening after controversial entrepreneur Martin Shkreli acquired a controlling a stake with plans to rescue KaloBios' lead asset.
Pfizer and Allergan are close to striking a deal that would be the biggest of 2015 by far--and the biggest healthcare deal ever, Bloomberg reports. The price: $370 to $380 per share, or almost $150 billion.
Charles River Laboratories, on the heels of some M&A-driven revenue growth, acquired another early-stage research company, paying $36 million for a German provider of drug discovery services.
If Pfizer does make a friendly deal for Allergan, CEO Ian Read will be giving up his seat at the helm. That's the word from sources at Pfizer, who told Forbes ' John LaMattina that current negotiations depend on Allergan CEO Brent Saunders taking charge at the combined company.
Private equity giant Warburg Pincus is diving into specialty pharmaceuticals, launching Vertice Pharma and promising to invest up to $300 million in the company as it scouts for buyable assets.
Medtronic just announced the acquisition of Scotland's Aircraft Medical, a maker of video laryngoscopes to facilitate successful intubation of breathing tubes into the trachea, for $110 million in cash.
Depomed agreed to pay $25 million for the rights to a novel pain treatment from Germany's Grünenthal, signing a deal that will also settle the company's long-running patent lawsuit against Endo Pharmaceuticals
Dan Loeb, the activist investor who once called for Amgen to break itself in two, is now advising the Big Biotech to consider merging with Allergan, according to Bloomberg.
With pharma M&A growing at a steady clip, pressure from activist shareholders is also reaching new heights. But drugmakers have a few tricks up their sleeve for warding off the unwanted attention, including blacklisting firms to prevent them from taking a stake in the company once a deal goes through.
Laparoscopic surgery startup SurgiQuest has forced the hand of a potential acquirer. Last week, SurgiQuest filed to raise up to $75 million in an IPO. Now Conmed has said it will buy the Milford, CT, company instead for $265 million.